1999至2021年中国因安全性问题撤市药物的系统调查与分析
该研究调查了1999至2021年中国因安全性问题撤市的30种药物,发现2012至2021年撤市数量增加,16种药物(53.3%)的撤市决策主要基于病例系列或病例对照研究证据,15种药物同时在中国和美国撤市,其中5种(33.3%)在同一年撤市。研究建议加强高质量证据、监管协调和信息共享以优化药物安全监测。
要点
- 1999至2021年中国因安全性问题撤市30种药物,2012至2021年撤市数量增加。
- 16种药物(53.3%)的撤市决策主要基于病例系列或病例对照研究证据。
- 15种药物同时在中国和美国撤市,其中5种(33.3%)在同一年撤市。
核心结论
- 法规颁布和先进被动与主动系统的发展增强了中国的药物警戒。
- 应加强高质量证据、与其他监管机构的协调以及沟通和信息共享,以优化药物安全监测和风险管理。
研究设计与样本
- 从中国NMPA、美国FDA网站、WHO产品综合清单、WHO Drug Information和WHO Pharmaceuticals Newsletter识别撤市药物。
- 检索中国知网、维普、万方、PubMed和Google Scholar获取撤市详细信息。
- 使用牛津循证医学中心标准评估支持撤市的证据水平。
主要发现
- 1999至2021年中国市场共撤市30种药物。
- 在中国药物监测稳定期(2012-2021年),撤市数量增加。
- 16种药物(53.3%)的撤市决定主要基于病例系列或病例对照研究证据。
- 15种药物在中国和美国市场均撤市,其中5种(5/15,33.3%)在中国和美国同一年撤市。
临床怎么用
- 临床应关注中国NMPA因安全性问题撤市的药物历史,避免使用已撤市药物。
- 在评估药物安全性时,注意病例系列或病例对照研究证据在撤市决策中的重要作用。
- 关注中美同步撤市药物信息,及时更新用药风险认知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Chinese National Medical Products Administration (NMPA) has emphasized proactive pharmacovigilance throughout the product life cycle in recent years. However, the safety-related withdrawal of drugs from the Chinese market has received less attention. OBJECTIVES: The primary aim of the study was to investigate the context of withdrawing a drug for safety reasons in China (between 1999 and 2021). METHODS: Withdrawn drugs were first identified from the Chinese NMPA and United States (US) Food and Drug Administration websites and the World Health Organization's (WHO's) consolidated list of products, WHO Drug Information, and WHO Pharmaceuticals Newsletter. We then searched the China National Knowledge Internet database, Chongqing VIP information database, Wanfang database, PubMed, and Google Scholar for drug withdrawal details. We used the Oxford Centre for Evidence-Based Medicine criteria to assess the levels of evidence that support withdrawing a drug. RESULTS: A total of 30 drugs were withdrawn from the Chinese market between 1999 and 2021. The number of withdrawals increased during the stable Chinese drug surveillance period (2012-2021). Evidence from case-series or case-control studies was primarily used to determine the withdrawals of 16 drugs (53.3%). Fifteen drugs were withdrawn from the markets of China and the US, including five drugs (5/15, 33.3%) that were withdrawn in the same year in China and the US. CONCLUSIONS: The promulgation of regulations and development of advanced passive and active systems have enhanced pharmacovigilance in China. High-quality evidence, coordination with other regulatory authorities, and communication and information sharing should be strengthened to optimize drug safety surveillance and risk management.
引用
- Li Y, Jiang Y, Wang H, et al. Safety-Related Drug Withdrawals in China Between 1999 and 2021: A Systematic Investigation and Analysis. Drug Saf. 2022. PMID: 35821561. doi:10.1007/s40264-022-01185-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。